Stock Taper
GNTA
GENENTA SCIENCE S.P.A.
NASDAQ
$0.99
▲ UP 3.23% (0.03)

KEY STATISTICS

Market Cap$18.96 M
52w High$10.00
52w Low$0.55
Dividend Yield
Frequency
P/E-1.36
Volume36.38K
Shares Out.19.15M

COMPANY

LEADERSHIP

Pierluigi Paracchi
CHIEF EXECUTIVE
Pierluigi Paracchi

ABOUT

SECTOR
Healthcare
WENT PUBLIC
December 15, 2021
METHOD OF GOING PUBLIC
SPAC
FULL TIME EMPLOYEES
9

UPCOMING EARNINGS

DateMar 3, 2027
DayWednesday
Rev. Est.
MAR
3
WED

PRICE

$0.99 ▲ UP 3.23% (+$0.03)
$0.96$0.97$0.98$0.999:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM0.99

About Genenta Science S.p.A.

https://www.genenta.com ↗

Genenta Science S.p.A. is an Italy-based clinical-stage biotech developing hematopoietic stem cell gene therapies, including Temferon for glioblastoma and other solid tumors.

INDUSTRY

Medical - Pharmaceuticals

A PRODUCT GENENTA SCIENCE S.P.A. IS KNOWN FOR

Temferon™
Temferon™

Temferon™ is a first-in-class hematopoietic stem cell gene therapy targeting solid tumors by delivering immune-therapeutic payloads within the tumor microenvironment, currently in clinical trials for glioblastoma and metastatic renal cell carcinoma.

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity2
Price To Earnings1
Price To Book4
Overall Score2

INSIDER TRADES

DIRECTOR, 10 PERCENT OWNER, OFFICER: CHIEF EXECUTIVE OFFICER
Paracchi Pierluigi
Purchase · 100.0K shares
2026-03-30
DIRECTOR
PARACCHI GIACOMOANTONIO
Purchase · 20.0K shares
2026-03-30
DIRECTOR
Mutti Miguel Maria
Purchase · 20.0K shares
2026-03-30
OFFICER: CHIEF FINANCIAL OFFICER
SLANSKY RICHARD B
Purchase · 80.0K shares
2026-03-30

SECTORS PEERS

PEERPRICE
IPSC$2.10COMPARE
TELO$1.22COMPARE
INMB$2.52COMPARE
SER$2.50COMPARE
BRNS$0.76COMPARE
SKYE$1.92COMPARE
MDCX$0.18COMPARE
JUNS$3.13COMPARE